JESSICA STEWART: Open Payments
NPI 1093157927 · RUSTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,139 in 138 payments from 20 companies in 2025. Trend: 2023 $2,091 · 2024 $2,041 · 2025 $3,139
Food & beverage: $3,139
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. | 30 | $995 |
| Bayer Healthcare Pharmaceuticals Inc. | 16 | $345 |
| Novo Nordisk Inc | 20 | $334 |
| Lilly USA, LLC | 12 | $201 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 12 | $193 |
| BETA BIONICS, INC. | 5 | $176 |
| Insulet Corporation | 7 | $160 |
| Sequel Med Tech, LLC | 5 | $109 |
| Corcept Therapeutics | 4 | $109 |
| Tandem Diabetes Care, Inc. | 5 | $91 |
Products named: Dexcom G6 Transmitter, Kerendia, JARDIANCE, MOUNJARO, iLet Bionic Pancreas, Omnipod, Ozempic, Rybelsus.
Industry payments across LA — which companies pay providers there.
